Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Threonine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.35 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 2/20 | 0.34 |
| ▸ | GRM8 | O00222 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Threonine SCHEMBL1031790 | 1.00 | USP2 (0.39) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| Threonine SCHEMBL21332591 | 0.96 | USP2 (0.41) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| Threonine SCHEMBL28173644 | 0.96 | USP2 (0.41) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| Threonine SCHEMBL2076959 | 0.96 | USP2 (0.41) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| Threonine SCHEMBL9228477 | 0.96 | USP2 (0.41) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| Threonine SCHEMBL9716088 | 0.93 | USP2 (0.44) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| Threonine SCHEMBL9716069 | 0.93 | USP2 (0.44) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| Threonine SCHEMBL1067383 | 0.93 | USP2 (0.44) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| Threonine SCHEMBL1697282 | 0.93 | USP2 (0.44) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 | |
| Threonine SCHEMBL1067389 | 0.93 | USP2 (0.44) | USP2SLCO1B1SLC7A5SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178612-A1 | SARS-COV-2 AND INFLUENZA COMBINATION VACCINE | Spicona Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022009121-A1 | SARS-COV-2 AND INFLUENZA COMBINATION VACCINE | SPICONA INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-1185631-B1 | NOVEL ENDO-BETA-1,4-GLUCANASES | NOVOZYMES AS (DK) | 2006-08-09 | — | — | EP | disclosed |
| EP-1185631-A1 | NOVEL ENDO-BETA-1,4-GLUCANASES | Novozymes A/S (DK) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001059083-A1 | BACTERIAL GALACTANASES AND USE THEREOF | NOVOZYMES A/S (DK) | 2001-08-16 | — | — | WO | disclosed |
| US-6165769-A | Pectin degrading enzymes from Bacillus licheniformis | NOVO NORDISK A/S (DK) | 2000-12-26 | — | — | US | disclosed |
| WO-2000073428-A1 | NOVEL ENDO-BETA-1,4-GLUCANASES | NOVOZYMES A/S (DK) | 2000-12-07 | — | — | WO | disclosed |
| US-6153420-A | PROTEIN WITH ENZYMATIC ACTIVITY; FOR THE DETECTION OF MODULATORS OR ENZYMATIC ACTIVITY; FOR CLEAVING PEPTIDE LINKAGE OF SUBSTRATE PROTEIN; FOR USE AS DIAGNOSTIC TOOLS IN GENETIC ENGINEERING | ZYMOGENETICS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-6143874-A | FOR STIMULATING B-CELL AND/OR T CELL PRODUCTION; ANTIINFLAMMATORY AGENTS; TREATMENT OF ALZHEIMER'S/PARKINSON'S DISEASES, AMYOTROPHIC LATERAL SCLEROSIS, AND VARIOUS DEGENERATIVE DISORDERS THAT AFFECT VISION | AMGEN INC (US) | 2000-11-07 | — | — | US | disclosed |
| US-6143720-A | FOR DETECTING GENETIC ABNORMALITY IN MAMMALS | ZYMOGENETICS, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-5914251-A | GENE FOR A POLYPEPTIDE WHICH ACTIVATES PROPAGATION OF PROSTATE AND EPITHELIAL TISSUES; DIAGNOSIS; ANTICARCINOGENIC/ANTITUMOR AGENTS | AMGEN INC. (US) | 1999-06-22 | — | — | US | disclosed |
| WO-1999002663-A1 | ALKALINE XYLOGLUCANASE | NOVO NORDISK A/S (DK) | 1999-01-21 | — | — | WO | disclosed |
| US-5859197-A | ISOLATED NEURITIN POLYPEPTIDE WHICH PROMOTES NEURITOGENESIS IN HIPPOCAMPAL OR CORTICAL NEURONAL CULTURES | AMGEN INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5817784-A | POLYPEPTIDE TERMINED NEURITIN WHICH IS EXPRESSED PRIMARY IN BRAIN TISSUE | AMGEN INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5792850-A | ISOLATED POLYNUCLEOTIDE ENCODING A POLYPEPTIDE AS A STIMULANT LIGAND-BINDING RECEPTOR | ZYMOGENETICS, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5766877-A | GENE EXPRESSION | AMGEN INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5741772-A | POLYPEPTIDE | AMGEN INC. (US) | 1998-04-21 | — | — | US | disclosed |
| US-5641655-A | GENETIC ENGINEERED DNA ENCODING A PROTEIN FUSION | ZYMOGENETICS, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0710253-A1 | ANTIBODIES SPECIFIC FOR HUMAN PROSTATE GLANDULAR KALLIKREIN | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1996-05-08 | — | — | EP | disclosed |
| WO-1995003334-A1 | ANTIBODIES SPECIFIC FOR HUMAN PROSTATE GLANDULAR KALLIKREIN | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1995-02-02 | — | — | WO | disclosed |